Factors impacting compliance with palivizumab prophylaxis.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007558:Italy; D008297:Male; D000069455:Palivizumab; D010349:Patient Compliance; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D012189:Retrospective Studies; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab